SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PE Biosystems (PEB)
PEB 11.32-1.4%Dec 31 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mel Spivak who wrote ()1/15/1998 12:07:00 PM
From: Don Dorsey  Read Replies (1) of 122
 
This news is a few days old, but here it is in case anybody missed it.

Quantech Ltd. Announces Completion of First Phase of Instrument Development

PR Newswire - January 08, 1998 16:09

ST. PAUL, Minn., Jan. 8 /PRNewswire/ -- Quantech Ltd.
(OTC Bulletin Board: QQQQ), today announced that it has completed the first
phase of instrument development pursuant to the company's Technology and
Development Agreement with The Perkin-Elmer Corporation (NYSE: PKN). The
agreement provides for phases of Quantech system development for which
Perkin-Elmer can provide technical assistance.
"This first phase has resulted in a stable breadboard-level instrument
that detects bulk changes of chemical concentrations," said Robert Case, CEO
of Quantech. "Although this breadboard is not sufficient to start FDA work,
it reflects a very significant technical milestone in overcoming many
stability problems faced in the past. The speed with which this phase was
completed was the result of assistance provided by Perkin-Elmer prior to the
signing of our technology and development agreement. With this phase
completed, we are proceeding with final development of the system that we will
use for the FDA submission."
Based in St. Paul, Minn., Quantech is a development stage company working
to commercialize its surface plasmon resonance ("SPR") technology for the
critical care medical diagnostic market. The company's diagnostic system is
designed for hospital critical care units, initially the emergency department,
to provide rapid, quantitative diagnostic results using whole blood.
Quantech's first tests will be used for detecting and quantifying cardiac
markers which aid physicians in assessing whether a patient has suffered a
heart attack. Additional tests are expected to be made available, allowing
the system to provide a full range of critical care and other testing
capabilities.

SOURCE Quantech Ltd.
/CONTACT: Curt Swenson of Swenson/Falker Associates Inc., Minneapolis for
Quantech, 612-371-0000 or Gregory Freitag of Quantech Ltd., 612-647-6370/
(QQQQ PKN)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext